Pay in 4 interest-free payments of $6.27 Learn more
Ships within 48 hours · Estimated delivery Oct 8 - Oct 13
Others lock you into three-month or six-month commitments with significant cancellation fees
Fiction As we move into 2026, the safety profile of these peptides is becoming clearer
Register now for exclusive savings and additional group discounts: URLs: Tickets: Brochure: Prices: Drug Developer Pricing | Conference Only: USD 2999.00, Academic Pricing | Conference Only : USD 2599.00, Standard Pricing | Conference Only: USD 3699.00 Speakers: Andrew Young - Chief Medical Officer - i2o Therapeutics, Eduardo Santos - Executive Director and Head of General Medicines, Therapeutic Areas, and Business Development | Global Value, Access, and Pricing - Amgen, Feng Liu - Executive Director | Research and Development - Regor Therapeutics, Ibrahim Turfanda - Senior Director | Next Generation Incretins | NILEX and Outcomes - Eli Lilly, Jo Bednarik - Executive Director | Medical Development, Diabetes, and Obesity - Eli Lilly, Jonathan Douros - Associate Director | Biology and Pharmacology - Novo Nordisk, Lars Johansson - Chief Scientific Officer - Antaros Medical, Leilani Morales - Global Chapter Lead | Medical Development and Evidence Generation - Roche, Maggie Kelleher - Senior Director/Team Lead | Commercial Strategy and Innovation Business Assessment | Internal Medicine and Digital - Pfizer, Manu Chakravarthy - Chief Scientific and Medical Officer - Carmot Therapeutics, Matthew Coghlan - Vice President and Head Incretin Portfolio Science - Eli Lilly, Paul Rubin - Chief Medical Officer - BioAge Labs, Scott Harris - Chief Medical Officer - Altimmune, Seulki Lee - Chief Executive Officer | D and D Pharmatech, Todd Hobbs - Chief Medical Officer - Diasome Pharmaceuticals Have a Question About this Festival
Both formulations are FDA-approved branded medications manufactured by Novo Nordisk, distinguishing them from compounded alternatives
H., Daley, M
US$ 24.51
US$ 29.88
US$ 27.47
US$ 21.52
